The SIGNAL-AA Part B phase IIa trial of bempikibart in severe and very severe alopecia areata showed a 35.3% mean SALT reduction and 40% SALT 20 response at 36 weeks, with a favorable safety profile and durable responses. These results support advancement to phase III and position bempikibart as a potential first-line biologic option.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.